Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

LianBio Starts China Trials of Gastric Cancer Therapy

publication date: Aug 25, 2021

LianBio, a Shanghai-Princeton in-licensing company, has started a China Phase IIa trial of infigratinib, an FGFR2 inhibitor. The trial will enroll patients who have gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 gene amplification. One year ago, LianBio acquired China rights to the candidate from BridgeBio as part of a two-drug, $531 million agreement. Infigratinib, which is approved in the US to treat cholangiocarcinoma with a FGFR2 fusion, is the first LianBio asset to start clinical trials. More details....

Stock Symbol: (NSDQ: BBIO)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China